中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2015年
1期
72-74
,共3页
密固达%骨密度%骨量%钙剂%活性维生素D%骨质疏松骨折
密固達%骨密度%骨量%鈣劑%活性維生素D%骨質疏鬆骨摺
밀고체%골밀도%골량%개제%활성유생소D%골질소송골절
Aclasta%Bone mineral density%Bone mass%Calcium%Activated vitamin D%Osteoporotic fracture
目的：探讨双膦酸盐对骨质疏松骨量的影响。方法选绝经后骨质疏松症患者59例，随机分为治疗组和对照组，其中治疗组（30例），一次性静脉滴注唑来膦酸注射液5 mg，后次日始日一次静点0?9％生理盐水100 ml＋葡萄糖酸钙10 ml（1g）3～5天，同时碳酸钙600 mg／d，活性维生素D3400IU／d口服；对照组（29例），给予同剂量的碳酸钙及活性维生素D3口服，6个月后复查评价疗效。结果患者临床疗效比较，治疗后患者BMD值有不同程度增高，其中骨含量一项升高明显，疼痛感明显下降，与治疗前比较，差异有统计学意义（P＜0?05），随访期间无一例骨质疏松性骨折发生。结论双膦膦酸联合钙剂治疗绝经后骨质疏松，能显著改善患者的疼痛症状，有效的改善及维持BMD 水平，增加骨量降低了骨质疏松骨折的发生率。是治疗绝经后骨质疏松症的安全有效方法。
目的：探討雙膦痠鹽對骨質疏鬆骨量的影響。方法選絕經後骨質疏鬆癥患者59例，隨機分為治療組和對照組，其中治療組（30例），一次性靜脈滴註唑來膦痠註射液5 mg，後次日始日一次靜點0?9％生理鹽水100 ml＋葡萄糖痠鈣10 ml（1g）3～5天，同時碳痠鈣600 mg／d，活性維生素D3400IU／d口服；對照組（29例），給予同劑量的碳痠鈣及活性維生素D3口服，6箇月後複查評價療效。結果患者臨床療效比較，治療後患者BMD值有不同程度增高，其中骨含量一項升高明顯，疼痛感明顯下降，與治療前比較，差異有統計學意義（P＜0?05），隨訪期間無一例骨質疏鬆性骨摺髮生。結論雙膦膦痠聯閤鈣劑治療絕經後骨質疏鬆，能顯著改善患者的疼痛癥狀，有效的改善及維持BMD 水平，增加骨量降低瞭骨質疏鬆骨摺的髮生率。是治療絕經後骨質疏鬆癥的安全有效方法。
목적：탐토쌍련산염대골질소송골량적영향。방법선절경후골질소송증환자59례，수궤분위치료조화대조조，기중치료조（30례），일차성정맥적주서래련산주사액5 mg，후차일시일일차정점0?9％생리염수100 ml＋포도당산개10 ml（1g）3～5천，동시탄산개600 mg／d，활성유생소D3400IU／d구복；대조조（29례），급여동제량적탄산개급활성유생소D3구복，6개월후복사평개료효。결과환자림상료효비교，치료후환자BMD치유불동정도증고，기중골함량일항승고명현，동통감명현하강，여치료전비교，차이유통계학의의（P＜0?05），수방기간무일례골질소송성골절발생。결론쌍련련산연합개제치료절경후골질소송，능현저개선환자적동통증상，유효적개선급유지BMD 수평，증가골량강저료골질소송골절적발생솔。시치료절경후골질소송증적안전유효방법。
Objective To explore the influence of bisphosphonates in bone mass in osteoporosis. Methods Fifty?nine patients with postmenopausal osteoporosis were selected and were randomly divided into treatment group ( n=30 ) and control group ( n=29). In treatment group, patients received intravenous 5mg zoledronic acid (Aclasta) injection once, and continued with 0?9%normal saline 100ml and calcium gluconate 10 ml (1g) once a day for 3-5 days. They also took calcium carbonate 600mg/d and active vitamin D3 400 iu/d. In control group, patients were given oral calcium 600 mg/d and active vitamin D3 400 iu/d. The efficacy was evaluated after 6 months. Results After the treatment, BMD of patients increased in varying degree. Bone mineral content was elevated significantly. The pain decreased significantly. The difference was statistically significant ( P < 0?05 ) compared with that before treatment. No osteoporotic fractures occurred during the follow?up. Conclusion Bisphosphonates combining with calcium can significantly relieve the pain symptom, improve and maintain the BMD level, increase bone mass and reduce the incidence of osteoporotic fractures in the treatment of postmenopausal osteoporosis. It is a safe and effective method for treatment of postmenopausal osteoporosis.
